three other compounds have been approved in Japan (Ipragliflozin, Tofogliflozin, Luseogliflozin), while others are in development (Ertugliflozin and Sotagliflozin) ( Canagliflozin Canagliflozin [(1 S )-1,5-andro-1-[3-[[5-(4-fluorophenyl)-2-tienil]metil]-4-metilfenil]-d- GLUCITOLO emirate], is a C-glycosyl compound that is used (in the hemihydrate form) for the treatment of T2DM through inhibition of sodium/glucose co-transporter 2 ( It was initially approved by the FDA in 2013 for the management of T2DM and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with T2DM
Real-time monitoring of emotional changes Real-time monitoring of emotional changes represents a critical application of AI in sentiment analysis
Note that for purposes of this article, firms were included in the OTC product category if the warning letter mentioned an OTC product
Permert J, Adrian TE, Jacobsson P, Jorfelt L, Fruin AB, Larsson J
MeAgain can help you keep a record
